Study of Early Cancer Biomarkers in Breath Condensate in Population of Individuals With High-Risk of Lung Cancer Undergoing LDCT Screening.
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Exhaled breath condensate sampling, Blood sampling, LDCT, Vital signs.
- Who it may be relevant to
- Registry conditions: Lung Cancer. Basic parameters: 55 years — 74 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Czechia
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Prospective Validation Study of Early Cancer Biomarkers in Breath Condensate of Individuals With High-Risk of Lung Cancer Undergoing Low-Dose Computer Tomography Based Screening.
Overview
The trial will evaluate if the newly identified biomarkers of lung cancer in exhaled breath condensate are as a diagnostic tool comparable to the low-dose computer tomography (LDCT) implemented in lung cancer screening recently. Due to the possibility to collect breath condensate at any medical workplace and due to the relatively low financial cost of examination of the collected breath condensate could improve early diagnosis of lung cancer, differential diagnostics of lung nodules and thereby reduce both the unnecessary interventions and deaths from this type of cancer.
Detailed description
The project aims to validate newly identified biomarkers of lung cancer in breath condensate for the diagnosis and triage of lung nodules (malignant versus benign), further set the mechanisms of the functioning of the lung cancer screening center, validate the quality indicators of LDCT screening for the Czech Republic and stratify the cohort of individuals so that optimized output of screening activities. Patients aged 55-74 years with a heavy smoking load (more than 20, preferably more than 30 pack/years) will be divided into risk groups according to biomarkers in exhaled air, clinical/anamnesis data and the degree of obstructive ventilation disorder according to spirometry and subsequently there will be effective stratification of the risk of lung carcinoma. The group with the highest risk of developing lung cancer will then be diagnosed with early lung cancer using ultra-low-dose computed tomography of the chest. This will lead to early diagnosis and subsequently to a reduction in the mortality rate of the monitored active group compared to the historical cohort. The primary outcome will be the validation of the multiplex protein signature in exhaled air, the effectiveness of the screening procedure to reduce lung cancer mortality and overall mortality in the group with FEV1 (forced expiratory volume at 1 second) pre-bronchodilation 60-75% with the entire group of examinees. The secondary outcome will then be the total time of diagnosis of a solitary pulmonary nodule in positively screened patients for whom only observation is not a sufficient procedure. Another secondary outcome will be the costs of screening procedures for individual groups and the percentage of success of the anti-smoking intervention for the enrolled individuals. The number of newly captured interstitial lung processes will also be evaluated. Patients will be evaluated for 5 years at annual visits or earlier based on their LDCT result.
Interventions
- Diagnostic test Exhaled breath condensate sampling
Patient will breath for approx. 10 minutes to a breath condenser. The exhaled breath sample will be condensed and freezed. - Diagnostic test Blood sampling
A venous blood sample will be taken for further biomarker analysis. - Procedure LDCT
LDCT scan will be performed. - Diagnostic test Vital signs
Blood pressure, weight, height, pulse, oxygen saturation will be measured. - Diagnostic test Spirometry
Spirometry will be performed.
Primary outcome measures
- Validation of the multiplex protein signature in exhaled air [Time frame: 5 years]
- Validation of the multiplex protein signature in exhaled breath for differential diagnostics of lung nodules [Time frame: 5 years]
- Assessment of the effectiveness of the screening program [Time frame: 5 years]
Secondary outcome measures (3)
- Total time of diagnosis of the nodule [Time frame: 5 years]
- Comparison of costs of screening procedures [Time frame: 5 years]
- Assessment of success of the anti-smoking intervention [Time frame: 5 years]
Eligibility criteria
Inclusion criteria
- Consent to participate in a clinical trial.
- A clients within an age of 55-74 years.
- Current smoker or ex-smoker who has smoked at least 20 pack-years, provided that:
- priority will be given to clients who have smoked at least 30 pack-years.
- preference will be given to a former smoker who has not smoked for less than 15 years.
Exclusion criteria
- Previous diagnosis of lung cancer.
- Progressing malignant tumor on symptomatic treatment.
- Advanced dementia
- Chronic obstructive pulmonary disease or other inflammatory disease in the phase of acute exacerbation.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: Yes
Study design
- Allocation
- N/A
- Model
- Single group
- Masking
- Open label
- Primary purpose
- Screening
Study locations
Czechia · 3 centers
- Masaryk Memorial Cancer Institute — Brno
- University Hospital — Olomouc
- General University Hospital in Prague — Prague
Identifiers
NCT: NCT06016569 · 60096